Feldman SR - Search Results

1

Definitions of measures of effect duration for psoriasis treatments.

Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G. Gordon KB, et al. Among authors: feldman sr. Arch Dermatol. 2005 Jan;141(1):82-4. doi: 10.1001/archderm.141.1.82. Arch Dermatol. 2005. PMID: 15655149 No abstract available.

2

Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?

Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A, Morison WL, Prystowsky JH, Shupack JL, Taylor JR, Weinstein GD, Barton TL, Rolstad T, Day RM. Krueger GG, et al. Among authors: feldman sr. J Am Acad Dermatol. 2000 Aug;43(2 Pt 1):281-5. doi: 10.1067/mjd.2000.106374. J Am Acad Dermatol. 2000. PMID: 10906652

3

A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis.

Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR. Lebwohl M, et al. Among authors: feldman sr. Int J Dermatol. 2002 May;41(5):269-74. doi: 10.1046/j.1365-4362.2002.01431.x. Int J Dermatol. 2002. PMID: 12100701 Clinical Trial.

4

Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors.

Menter MA, Krueger GC, Feldman SR, Weinstein GD. Menter MA, et al. Among authors: feldman sr. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S39-43. doi: 10.1016/mjd.2003.545. J Am Acad Dermatol. 2003. PMID: 12894124 No abstract available.

5

Combination therapy to treat moderate to severe psoriasis.

Lebwohl M, Menter A, Koo J, Feldman SR. Lebwohl M, et al. Among authors: feldman sr. J Am Acad Dermatol. 2004 Mar;50(3):416-30. doi: 10.1016/j.jaad.2002.12.002. J Am Acad Dermatol. 2004. PMID: 14988684 Review.

6

Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis.

Feldman SR, Menter A, Koo JY. Feldman SR, et al. Br J Dermatol. 2004 Feb;150(2):317-26. doi: 10.1111/j.1365-2133.2004.05697.x. Br J Dermatol. 2004. PMID: 14996104 Clinical Trial.

7

Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.

Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Stern RS, et al. Among authors: feldman sr. J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9. doi: 10.1046/j.1087-0024.2003.09102.x. J Investig Dermatol Symp Proc. 2004. PMID: 15083780 Free article.

8

A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.

Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. Carlin CS, et al. Among authors: feldman sr. J Am Acad Dermatol. 2004 Jun;50(6):859-66. doi: 10.1016/j.jaad.2003.09.014. J Am Acad Dermatol. 2004. PMID: 15153885

9

Determinants of quality of life in patients with psoriasis: a study from the US population.

Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Gelfand JM, et al. Among authors: feldman sr. J Am Acad Dermatol. 2004 Nov;51(5):704-8. doi: 10.1016/j.jaad.2004.04.014. J Am Acad Dermatol. 2004. PMID: 15523347

10

The prevalence of psoriasis in African Americans: results from a population-based study.

Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, Margolis DJ. Gelfand JM, et al. Among authors: feldman sr. J Am Acad Dermatol. 2005 Jan;52(1):23-6. doi: 10.1016/j.jaad.2004.07.045. J Am Acad Dermatol. 2005. PMID: 15627076

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,463 results

Search Page

Filters